Cost of coils for intracranial aneurysms: clinical decision analysis for implementation of a capitation model

Restricted access

OBJECTIVE

The price of coils used for intracranial aneurysm embolization has continued to rise despite an increase in competition in the marketplace. Coils on the US market range in list price from $500 to $3000. The purpose of this study was to investigate potential cost savings with the use of a price capitation model.

METHODS

The authors built a clinical decision analytical tree and compared their institution’s current expenditure on endovascular coils to the costs if a capped-price model were implemented. They retrospectively reviewed coil and cost data for 148 patients who underwent coil embolization from January 2015 through September 2016. Data on the length and number of coils used in all patients were collected and analyzed. The probabilities of a treated aneurysm being ≤/> 10 mm in maximum dimension, the total number of coils used for a case being ≤/> 5, and the total length of coils used for a case being ≤/> 50 cm were calculated, as was the mean cost of the currently used coils for all possible combinations of events with these probabilities. Using the same probabilities, the authors calculated the expected value of the capped-price strategy in comparison with the current one. They also conducted multiple 1-way sensitivity analyses by applying plausible ranges to the probabilities and cost variables. The robustness of the results was confirmed by applying individual distributions to all studied variables and conducting probabilistic sensitivity analysis.

RESULTS

Ninety-five (64%) of 148 patients presented with a rupture, and 53 (36%) were treated on an elective basis. The mean aneurysm size was 6.7 mm. A total of 1061 coils were used from a total of 4 different providers. Companies A (72%) and B (16%) accounted for the major share of coil consumption. The mean number of coils per case was 7.3. The mean cost per case (for all coils) was $10,434. The median total length of coils used, for all coils, was 42 cm. The calculated probability of treating an aneurysm less than 10 mm in maximum dimension was 0.83, for using 5 coils or fewer per case it was 0.42, and for coil length of 50 cm or less it was 0.89. The expected cost per case with the capped policy was calculated to be $4000, a cost savings of $6564 in comparison with using the price of Company A. Multiple 1-way sensitivity analyses revealed that the capped policy was cost saving if its cost was less than $10,500. In probabilistic sensitivity analyses, the lowest cost difference between current and capped policies was $2750.

CONCLUSIONS

In comparison with the cost of coils from the authors’ current provider, their decision model and probabilistic sensitivity analysis predicted a minimum $407,000 to a maximum $1,799,976 cost savings in 148 cases by adapting the capped-price policy for coils.

Article Information

Correspondence Brian T. Jankowitz, Department of Neurological Surgery, University of Pittsburgh Medical Center, 200 Lothrop St., Ste. B400, Pittsburgh, PA 15213. email: jankbt@upmc.edu.

INCLUDE WHEN CITING Published online August 25, 2017; DOI: 10.3171/2017.3.JNS163149.

Disclosures Dr. Jovin reports a consultant relationship with Anaconda and Johnson & Johnson and direct stock ownership in Silk Road Medical and Blockade Medical.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Bar graph depicting the number of coils used from all providers. Figure is available in color online only.

  • View in gallery

    Folded-back decision tree depicting the expected value of each strategy along with the probabilities and cost for each event. An = aneurysm; p = probability. Figure is available in color online only.

  • View in gallery

    Tornado diagram depicting multiple 1-way sensitivity analyses of studied variables. An = aneurysm; c = cost; p = probability. Figure is available in color online only.

  • View in gallery

    Cumulative likelihood of cost difference between buying from Company A and using the capped policy. Figure is available in color online only.

References

1

Kashlan ONWilson TJChaudhary NGemmete JJStetler WR JrDunnick NR: Reducing costs while maintaining quality in endovascular neurosurgical procedures. J Neurosurg 121:107110762014

2

Maeda JLRaetzman SOFriedman BS: What hospital inpatient services contributed the most to the 2001–2006 growth in the cost per case? Health Serv Res 47:181418352012

3

McDougall CGJohnston SCGholkar ABarnwell SLVazquez Suarez JCMassó Romero J: Bioactive versus bare platinum coils in the treatment of intracranial aneurysms: the MAPS (Matrix and Platinum Science) trial. AJNR Am J Neuroradiol 35:9359422014

4

Molyneux AJClarke ASneade MMehta ZColey SRoy D: Cerecyte coil trial: angiographic outcomes of a prospective randomized trial comparing endovascular coiling of cerebral aneurysms with either cerecyte or bare platinum coils. Stroke 43:254425502012

5

Rosenbaum LLamas D: Cents and sensitivity—Teaching physicians to think about costs. N Engl J Med 367:991012012

6

White PMLewis SCGholkar ASellar RJNahser HCognard C: Hydrogel-coated coils versus bare platinum coils for the endovascular treatment of intracranial aneurysms (HELPS): a randomised controlled trial. Lancet 377:165516622011

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 230 230 82
Full Text Views 390 390 32
PDF Downloads 195 195 32
EPUB Downloads 0 0 0

PubMed

Google Scholar